Vapreotide
Somatostatin AnalogAlso known as: RC-160
A synthetic somatostatin analog studied for variceal bleeding & carcinoid syndrome. Available in some European countries.
Typical Dose
25 mcg bolus then 25 mcg/h IV infusion (variceal bleeding)
Route
Intravenous infusion or SubQ
Cycle
Acute (5 days for variceal bleeding)
Half-life
~1–2 hours
Storage
Per manufacturer.
Overview
Vapreotide is a synthetic somatostatin analog used in some countries for acute variceal bleeding (splanchnic vasoconstriction) & carcinoid syndrome. Less widely used than octreotide; limited to specific indications in selected markets.
Quick Start Guide
Clinical use only under physician supervision.
Research Indications
Acute variceal bleeding
EffectiveReduces portal pressure via splanchnic vasoconstriction. Similar to octreotide for acute use.
Side Effects & Safety
Common
- Nausea
- Hyperglycemia
- Bradycardia
Uncommon
- Hypoglycemia
When to Stop
- Signs of allergic reaction
- Significant bradycardia
How to Reconstitute
Commercial product for clinical use.
Dosing math: Clinical use only.
Quality Indicators
Good — use as normal
- Per manufacturer
Discard immediately
- Per manufacturer
What to Expect
First 5 days
Variceal bleeding control.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample